Alerts will be sent to your verified email
Verify Email
GUFICBIO
|
Gufic Biosciences
|
Wanbury
|
Venus Remedies
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceutical Sector
|
|||
|
R&D as a % of Total Sales
|
1.06 % | n/a | n/a |
|
Financials
|
|||
|
5 yr Average ROE
|
26.14 % | -68.24 % | 3.75 % |
|
5yr average Equity Multiplier
|
2.82 | -5.8 | 1.64 |
|
5yr Average Asset Turnover Ratio
|
1.1 | 1.45 | 0.78 |
|
5yr Avg Net Profit Margin
|
9.03 % | 4.37 % | 2.2 % |
|
Price to Book
|
6.69 | 18.36 | 1.02 |
|
P/E
|
41.38 | 9.16 | 17.41 |
|
5yr Avg Cash Conversion Cycle
|
-18.02 Days | -125.27 Days | 62.86 Days |
|
Inventory Days
|
77.22 Days | 19.82 Days | 110.85 Days |
|
Days Receivable
|
81.36 Days | 46.87 Days | 37.87 Days |
|
Days Payable
|
175.58 Days | 189.66 Days | 50.32 Days |
|
5yr Average Interest Coverage Ratio
|
10.3 | 1.85 | 42.3 |
|
5yr Avg ROCE
|
33.27 % | -65.2 % | 5.53 % |
|
5yr Avg Operating Profit Margin
|
17.37 % | 6.05 % | 12.68 % |
|
5 yr average Debt to Equity
|
0.73 | -1.62 | 0.38 |
|
5yr CAGR Net Profit
|
29.43 % | -15.99 % | n/a |
|
5yr Average Return on Assets
|
10.17 % | 6.04 % | 3.42 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
72.51 % | 39.79 % | 41.76 % |
|
Share Pledged by Promoters
|
0.0 | 71.05 % | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
6.76 % | -12.3 % | 5.87 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-6.16 % | 0.0 | 0.0 |
|
Gufic Biosciences
|
Wanbury
|
Venus Remedies
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|